Company intelligence / Profile preview

Guangdong Techpool Bio-pharma

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Guangdong Techpool Bio-pharma is a leading Chinese manufacturer of bioprotein pharmaceuticals and enzyme replacement therapies with approved drugs for acute and chronic pancreatitis, cerebral infarction, shock, myocardial infarction, and sexual dysfunction, along with a preclinical oncolytic virus program targeting colorectal cancer[2][3].

Therapeutic areas: PsychiatryMen's HealthGastroenterologyCardiovascularOncologyNeurologyWomen's Health
Modalities: Enzyme replacement therapySmall moleculeOncolytic virus therapyRecombinant protease
Industry: Biotech

Drug pipeline

1 asset

Human urinary kallidinogenase

Partnerships

Nycomed (previous strategic/ownership relationship)[8]Takeda (previous joint venture partner/divestor)[2]Shanghai Pharma (majority owner and operator)[2]

Beyond the preview

Go deeper on Guangdong Techpool Bio-pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guangdong Techpool Bio-pharma.

Explore the full profile